ProjectsItalian Version
| Date | Title | Synopsis and Results | Proposer |
|---|---|---|---|
| 2026-05-31 | Foreign-born Individuals’ Profile and Access to Care in Multiple Sclerosis – Evidence from the Italian Registry of Multiple Sclerosis (IMPACT-MS study) | In recent years, Italy has seen a significant increase in its foreign-born population, with over 874,000 people arriving between 2023 and 2024 alone, and more than 5.4 million currently residing in the country. Many come from regions affected by conflict, such as Ukraine and the Middle East, potentially bringing new challenges to the Italian health ... read more |
Michela Ponzio |
| 2026-05-31 | Stop or not the disease-modifying therapies in secondary progressive multiple sclerosis: a comparison study of disability accrual trajectory. | Scant evidence is described about the necessity to stop or continue disease-modifying therapies (DMTs) in patients with relapsing remitting forms of multiple sclerosis (RRMS) who evolved into secondary progressive form (SPMS).
No guidelines exist about the exact moment in which DMTs must be stopped. This is associated to enormous costs and burden ... read more |
Emanuele D'Amico |
| 2026-05-31 | Use of Machine Learning techniques in predicting the course of relapsing-remitting Multiple Sclerosis in individual patients. | ... read more |
Marco Salvetti |
| 2026-05-31 | New generation of sphingosine 1-phosphate (S1P) receptor modulators in clinical practice: a real-world study from the Italian MS Registry | A second generation of sphingosine 1-phosphate (S1P) receptor modulators (siponimod, ozanimod and ponesimod), have been recently approved for the treatment of multiple sclerosis (MS). Siponimod and ozanimod are on the Italian commercial market since April 2021 and September 2021, respectively. Ponesimod is going to be on the Italian market. The eff ... read more |
Roberto Bergamaschi |
| 2026-05-31 | Optimal responders to platform disease modifying therapies in an Italian cohort of relapsing-onset multiple sclerosis patients | Objectives: in a large cohort of multiple sclerosis (MS) patients with relapsing onset, the primary objective of the project is to identify the proportion of "optimal responders" to platform therapies and to compare their clinical characteristics at baseline with those of "poor responder" and patients who start highly effective therapies. The secon ... read more |
Emilio Portaccio |
| 2026-05-31 | Characterization of non-active secondary progressive multiple sclerosis: diagnosis challenge ad assessment of progression independent from relapse activity phenomena | The clinical course of multiple sclerosis (MS) is currently described as a continuum of neuroinflammation and neurodegeneration, which challenges the classic distinction in clinical phenotype. (1-4) Relapse-associated worsening (RAW) combined with progression independent of relapse activity (PIRA) are detectable throughout the disease course. (5-9) ... read more |
Pietro Iaffaldano |
| 2026-05-31 | Assessment of cladribine therapy over time: effectiveness, safety and evaluation of treatment sequencing beyond year four | In the constantly evolving scenario of disease-modifying therapies (DMTs) in multiple sclerosis (MS), the advent of immune reconstitution therapy (IRT), administered in short-dosing periods to produce long-term immunological effects, offered the neurologist an additional tool against the irreversible disability accrual. (1-4) Cladribine is an oral ... read more |
Pietro Iaffaldano |
| 2026-05-31 | The impact of sex/gender on epidemiology, access to health facilities and treatment approach in people with multiple sclerosis. Results from the Italian Multiple Sclerosis and Related Disorders Register | Both sex and gender have been found to play important roles in various diseases and are crucial social determinant of health. The presence of female/male inequalities can limit access to healthcare, ultimately jeopardizing health and well-being. To improve the effectiveness of health systems, it is essential to pay closer attention to the actual di ... read more |
Eleonora Tavazzi |
| 2026-05-31 | Impact of the 2017 McDonald Criteria Revision on Time to Diagnosis and Long-Term Disability in Primary Progressive Multiple Sclerosis’s patients | The clinical course of relapsing multiple sclerosis (RMS) has become milder over recent decades [1]. Longitudinal cohort studies have consistently demonstrated a temporal delay in the attainment of disability milestones among patients diagnosed in more recent years [2–3-4]. Although this improvement results from a complex interplay of multiple fact ... read more |
Pietro Iaffaldano |
| 2026-05-31 | Comparative effectiveness of IV cyclophosphamide therapy versus no- or siponimod-treatment in delaying disability accrual in Secondary Progressive Multiple Sclerosis. | Effectiveness of available disease-modifying treatments (DMTs) on disability progression in multiple sclerosis (MS) is marginal, hence therapeutic options for secondary progressive (SP) MS are still limited;[1] siponimod is indeed the only DMT approved specifically for SPMS in Europe.[2] The lack of effective DMTs is probably due to the contributio ... read more |
Luca Massacesi |
| 2025-12-31 | Immunisation status against major communicable diseases preventable with vaccines, and safety of vaccines, in a cohort of multiple sclerosis patients. An italian multicenter study | ... read more |
Monica Ulivelli |
| 2025-12-31 | Evaluating Age-Dependent Efficacy of Multiple Sclerosis Treatments in a Real-Life Cohort | The role of age and ageing in Multiple Sclerosis (MS) is becoming increasingly important since epidemiological studies worldwide showed an ever-growing prevalence of MS in older age, which nowadays in many countries has been demonstrated to peak between 55-59 years, altogether with a relatively stable incidence of the disease. Many possible causes ... read more |
Maria Pia Amato/Fonderico |
| 2025-11-10 | Evaluating the effectiveness of Rituximab in rElapsiNg Multiple Sclerosis patiEnts previously treated with hiGhly-Active Disease modifying thErapies (RENEGADE). | Introduction: Active Multiple Sclerosis (MS) management requires the use of high-efficacy disease-modifying therapies (DMTs) such as fingolimod (FTY), natalizumab (NTZ), cladribine (CLD) or alemtuzumab (ALM) in order to reduce relapse activity, disability accrual and irreversible brain atrophy [1]. However, some patients are needed to suspend these ... read more |
Francesco Patti |
| 2025-01-31 | Air pollution as a risk factor of multiple sclerosis. An ecological study in the Italian population (The AIRMUS study) | ... read more |
Roberto Bergamaschi |
| 2025-01-31 | Comparative Effectiveness of Cladribine versus S1PR Modulators in Naive Patients with Relapsing-Remitting Multiple Sclerosis: An Observational Study | The primary objective of this study is to assess and compare the overall NEDA-3 status, as well as individual components of NEDA-3, treatment persistence, and safety profiles in patients diagnosed with RRMS, in patients who have undergone treatment with either Cladribine or S1PR modulators as their initial DMT, and who have a minimum follow-up per ... read more |
Shalom Haggiag |
| 2025-01-31 | Integrating genetic and phenotypic data from the PROGEMUS data-base and the Italian Multiple Sclerosis registry | ... read more |
Maurizio Leone |
| 2025-01-31 | Clinical and radiological prognostic predictors in Neuromyelitis Optica Spectrum Disorders (NMOSD) and MOG Antibody-mediated Disorders (MOGAD). Evaluation by Italian MS Registry and implementation of a disease-specific dataset | ... read more |
Tortorella Carla |
| 2025-01-31 | Clinical and neuroradiological findings in patients with late-onset multiple sclerosis (LOMS) | ... read more |
Francesco Patti |
| 2025-01-31 | Comprehensive Analysis of Real-World Data for NMO Patients Treated with Eculizumab, Satralizumab, Rituximab, and Inebilizumab: Is it time for a personalized treatMent Approach? (OPTIMA study) | The treatment of neuromyelitis optica (NMO), a debilitating autoimmune disorder characterized by severe and recurrent attacks of optic neuritis and myelitis, has significantly evolved with the advent of targeted therapies. Among the most promising treatments are rituximab, eculizumab, inebilizumab, and satralizumab. These therapies, which target sp ... read more |
Francesco Patti |
| 2025-01-31 | Evaluating the clinicAl and MRI characteristics of Secondary Progressive multiplE sclerosis; a registRy-bAsed/multicentric cohort study (ASPERA). | Give a clear view of aims, phases and methods (max 3.000 characters)
Introduction: Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system (CNS), with an unpredictable course [1, 2]. Relapsing-remitting (RRMS) and secondary progressive MS (SPMS) are commonly considered as part of a disease continuum each with ‘activ ... read more |
Francesco Patti |
| 2025-01-31 | Multi-centre, prospective/retrospective, randomised, open label pragmatic trial to compare the effectiveness and safety of interferon beta-1a (IFN beta-1a) administered weekly i.m. and glatiramer-acetate (GA) in pediatric patients affected by multiple sclerosis. | This study is a Phase IIIb, 36-month multi-centre, interventional prospetic/retrospective, pragmatic, open label, randomised trial to evaluate the effectiveness and safety of Glatiramer Acetate (GA) compared to Interferon beta-1a (INF beta-1a) in children/adolescent patients aged 12-17 (i.e. have not yet had their 18th birthday at randomisation) wi ... read more |
Marta Simone |
| 2025-01-31 | Towards an unified definition of progression independent of relapse activity in relapsing multiple sclerosis | Both controlled clinical trials and observational studies provided unequivocal evidence that steady progression independent of relapse activity (PIRA) is a frequent feature across the full spectrum of traditional multiple sclerosis (MS) phenotypes, including clinically isolated syndromes (CIS). PIRA occurs in approximately one quarter of early rela ... read more |
Emilio Portaccio |
| 2025-01-31 | Phenotyping progression in multiple sclerosis | Aims. This project is designed to identify crucial clinical and conventional MRI features that can precisely forecast distinct multiple sclerosis disability progression profiles over time. Our primary goal is to characterise disability profiles through a data-driven methodology and identify the baseline clinical and MRI features with the most robus ... read more |
De Meo / Amato |
| 2023-12-31 | Secondary prevention in multiple sclerosis: “Bacille Calmette-Guérin" (BCG) vaccine in people with radiologically isolated syndrome (RIS). | ... read more |
Giovanni Ristori |
| 2023-12-31 | SARS-CoV-2 pandemic as a model to assess the relationship between intercurrent viral infections and disease activity in Multiple Sclerosis: a propensity score matched case-control study | The association between intercurrent viral respiratory infections and exacerbations of
Multiple Sclerosis (MS) disease activity has been for many years an open question.
This is a propensity score matched, case-control, observational study in a single-center
cohort of patients with relapsing-remitting MS (RRMS) who tested positive for SARS-CoV-2
in ... read more |
Paola Cavalla |
| 2023-12-31 | Evaluating the efficacy of Ocrelizumab in Primary PrOgRessive mulTiple sclerosis: a mUlticeNter retrospectIve sTudY (OPPORTUNITY). | ... read more |
Francesco Patti |
| 2022-12-31 | Multiple Sclerosis disease activity and SARS-COV2 pandemic: a population based study from the Italian MS Registry | ... read more |
Marco Capobianco |
| 2022-12-31 | OCREVID Study (The management of OCRElizumab during the coVID-19 pandemic in Italy) | ... read more |
Antonio Gallo |
| 2022-12-01 | Validate a case definition of multiple sclerosis (MS) using different electronic (health and social) record: case study on selected provinces of Emilia Romagna Region. | ... read more |
Mario Alberto Battaglia |
| 2022-09-30 | PROfiling the risk of Severe Adverse Events during sequencing therapies in patients with multiple sclerosis: an observational cohort analysis based on Italian Multiple Sclerosis Registry. | ... read more |
Damiano Paolicelli |
| 2022-06-15 | Early prediction of unfavorable evolution of Clinically Isolated Syndrome (CIS) patients | In the last years there is a growing interest about patients with clinically isolated syndrome (CIS) suggestive for multi-focal inflammatory demyelinating disease of the central nervous system. These cases can evolve to clinically definite multiple sclerosis (CDMS), before which a disease-free status can last for an unpredictable time. Recently, th ... read more |
Roberto Bergamaschi |
| 2022-05-26 | HETEROGENEITY Study. Are multiple sclerosis (MS) phenotypes influenced by the type of referral MS center? | ... read more |
Roberto Bergamaschi |
| 2022-05-26 | Demographic, clinical and treatment factors associated with the risk and severity of Covid-19 in people with Multiple Sclerosis | ... read more |
Maria Trojano |
| 2022-05-26 | Exploring phenotype and recovery from relapses in relapsing-remitting multiple sclerosis patients: old versus new Disease-Modifying Therapies | ... read more |
Emanuele D'Amico |
| 2022-05-26 | Clinical characteristics and disease outcomes of late onset Multiple Sclerosis: a retrospective multicenter study. | ... read more |
Lorena Lorefice |
| 2022-05-26 | Comparative effectiveness of different Natalizumab dosing schedules in real world life: a retrospective Italian multicentre study | ... read more |
Francesco Patti |
| 2022-05-26 | Comparative effectiveness of initial Treatment Choices for Multiple Sclerosis: a multicentre study | ... read more |
Emanuele D'Amico |
| 2022-04-26 | Silent progression in an Italian CIS and Relapsing-Remitting MS cohort | Objectives. To analyze, in a big Italian multicentric cohort of CIS and RRMS patients, data regarding the silent disease progression independent from relapse activity and MRI data, comparing treated - with "platform" and "highly active" therapies - and untreated patients.
Methods. Patients with: age >18 years; a CIS or RRMS diagnosis made using the ... read more |
Maria Pia Amato - Bellinvia |
| 2021-12-31 | Assessing early clinical and MRI predictors of treatment response in pediatric multiple sclerosis patients. | ... read more |
Maria Pia Amato/De Meo |
| 2021-12-31 | Big Multiple Sclerosis Data (BMSD) network | ... read more |
Maria Trojano |
| 2021-12-31 | Autologous Hematopoietic Stem Cell Transplantation For Secondary Progressive Multiple Sclerosis: a comparative study with matched control patients from the Italian Multiple Sclerosis Register | ... read more |
Matilde Inglese |
| 2021-12-31 | The concept of persistence in disability improvement: an application of Markov model to treated patients from the Italian Registry | ... read more |
Matilde Inglese |
| 2021-10-28 | EPID-MS Evaluation of the drivers of the therapy switch in active RRMS and active SPMS patients. | ... read more |
Maria Trojano-Pietro Iaffaldano |
| 2020-11-01 | Assessing Efficacy and Safety of treatments in progressive Multiple Sclerosis | Except for Ocrelizumab, previous phase-III randomized controlled trials largely failed in finding benefit of disease modifying drugs (DMDs) among patients affected by primary progressive multiple sclerosis (PPMS). Consistently with these findings, most of the Real word studies drove to the same conclusion, finding no substantial differences between ... read more |
Maria Pia Amato |
| 2020-10-15 | E-MUSIC: Early MUltiple Sclerosis Italian Cohort | Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS) that is characterized by inflammation, demyelination, and degenerative changes. Most individuals are diagnosed with MS at age 20–40 years. Pediatric-onset MS (POMS), before the age of 18, represents 3-10% of the whole MS population, while late-onset ... read more |
Maria Pia Amato-Mattia Fonderico |
| 2020-09-15 | Predictive factors of disability progression in a large cohort of italian multiple sclerosis patients | Multiple sclerosis (MS) is one of the most common cause of neurological disability in young adults globally. It is a chronic degenerative illness and therefore carries a high economic and quality of life burden associated with it. One of the principal objectives in the care of people with MS is, therefore, to reduce the irreversible accumulation of ... read more |
Marzia Romeo |
| 2020-07-15 | INTEREST. Italian Multiple Sclerosis Registry non interventional retrospective analysis in secondary progressive multiple sclerosis | The distinction between relapsing-remitting (RR) MS and progressive phenotypes remains a critical challenge for the neurologist in real clinical practice: currently there are not specific parameters or validated biomarkers to address the diagnostic doubt, which remains entrusted to clinical experience. In fact, in clinical practice secondary progre ... read more |
Maria Trojano |
| 2020-06-15 | Risks associated with Wash-Out Duration when switching from Fingolimod to cell-depleting agents | Decisions regarding the duration of washout periods between disease-modifying therapies (DMTs) in multiple sclerosis (MS) patients need to take both the risk of disease reactivation and safety issues regarding overlapping immunological mechanisms of action into account.
Fingolimod is an oral DMT, approved for the treatment of highly active relapsin ... read more |
Diana Ferraro |
| 2020-06-15 | Assessing the clinical course of pediatric onset multiple sclerosis in different treatment eras: are we really modifying the disease? | Availability of new disease modifying therapies (DMTs) and changes of therapeutic paradigms have led to a general improvement of multiple sclerosis (MS) prognosis in adults. It is still unclear if this improvement also involves pediatric-onset MS (POMS) patients, whose early management is limited by a low number of approved DMTs and, possibly, othe ... read more |
Damiano Baroncini |
| 2020-06-15 | Early-aggressive treatment algorithm versus classical escalation therapy in relapsing Multiple Sclerosis | The most important goal of multiple sclerosis (MS) therapy is the prevention of long-term disability accumulation. The therapeutic scenario for relapsing–remitting MS (RRMS) has widely expanded during the past 20 years. Choosing the MS therapy has become increasingly complex, due to the difficulties in weighing the risk/benefit ratio of several dif ... read more |
Maria Trojano-Pietro Iaffaldano |
| 2020-06-15 | Retrospective pilot study on long-term Cladribine effects in patients with relapsing remitting multiple sclerosis or clinically isolated syndrome. | The aim of this Italian pilot study call CLARINET-MS study is to explore the feasibility of the retrospective approach for evaluating effectiveness in subjects previously treated with Cladribine and then followed as per clinical practice.
The CLARINET-MS study assessed the long-term effectiveness of cladribine tablets by following patients with mu ... read more |
Francesco Patti |
| 2020-04-24 | The use of a roving EDSS reference value to enhance detection of EDSS worsening events: A real world evaluation through the Italian MS Register. | Disease registries are recognized as providing meaningful information on the burden, natural history, and long-term safety and effectiveness of treatments for patients with chronic diseases. Data collected in a register are also useful for observational research on sample populations treated and followed in real-world conditions. The result provide ... read more |
Paola Mosconi |
| 2019-12-15 | Retrospective study to evaluate the long-term impact of different treatment strategies on disability outcomes in patients with Relapsing Multiple Sclerosis. Italian IMedWeb MS Registry. RE.LO.DI.MS Study | The increase in disease-modifying drugs (DMDs) allows individualization of treatment in relapsing multiple sclerosis (RMS); however, the long-term impact of different treatment sequences is not well established. This is particularly relevant for MS patients who may need to postpone more aggressive DMD strategies.
To evaluate different therapeutic s ... read more |
Damiano Paolicelli |
| 2019-06-15 | INSPIRA - Italian analysis of the National multiple sclerosis registry Studying the concept of Progression Independent from Relapse Activity | To date, secondary-progressive multiple sclerosis (SPMS) is diagnosed retrospectively by neurologists, according to the Lublin’ definition: a history of a gradual disability progression, independent of relapses, after an initial relapsing course. No biological nor clinical markers are available to make more sensitive and reliable the identification ... read more |
Maria Trojano-Pietro Iaffaldano |
| 2017-10-14 | Profiling treatment choices in MS during two different eras: a real world assessment in the Italian MS Registry | ... read more |
Maria Trojano-Pietro Iaffaldano |